Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review
on Toxicity Profiles

Tyrosine kinase inhibitors (TKIs) have emerged as the mainstay treatment for renal cell carcinoma (RCC). Despite growing popularity of TKIs, the treatment safety and tolerability in elderly patients are yet to be fully understood. As new assessment tools become available in identifying elderly patients with cancer at risk for severe treatment-related toxicities, much remains to be learned about how to integrate these tools into our management of elderly patients with cancer. We present a case of a 75- year-old man with RCC who was initially treated with pazopanib and subsequently treated with sunitinib. We review the safety and toxicity profiles of TKIs in treating elderly patients with RCC.

Отказ от ответственности: Этот реферат был переведен с помощью инструментов искусственного интеллекта и еще не прошел проверку или верификацию

Архивы исследований рака

Индексировано в

Поделиться этой страницей

Абстрактный

Tyrosine Kinase Inhibitors in the Elderly: A Case Report and Literature Review on Toxicity Profiles